ILiAD Biotechnologies

About:

ILiAD is a clinical-stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis.

Website: http://iliadbio.com/

Twitter/X: iliadbio

Top Investors: National Institute of Allergy and Infectious Diseases, Knott Partners, Network-1, Endo Investors, Seedlings Life Science Ventures

Description:

ILiAD Biotechnologies (ILiAD) is a clinical-stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis. ILiAD's lead candidate is BPZE1, a live-attenuated pertussis vaccine that has successfully completed a Phase 1 human clinical trial. ILiAD Biotechnologies is a registered Delaware company founded in 2012.